Cancer Survivor Clinical Trial
Official title:
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Congestive Heart Failure (PREVENT-CHF): A Phase IIB Randomized Placebo-Controlled Trial
Verified date | March 2022 |
Source | City of Hope Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized phase II trial studies the side effects and how well low-dose carvedilol works in preventing congestive heart failure (CHF) in younger cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Carvedilol may help lower the risk of cardiovascular complications
Status | Active, not recruiting |
Enrollment | 250 |
Est. completion date | December 1, 2022 |
Est. primary completion date | June 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - Cancer diagnosis prior to 22 years of age, irrespective of current age - Lifetime cumulative anthracycline dose: >= 300 mg/m^2 without the protection of dexrazoxane (Zinecard) therapy - Time from completion of cancer treatment to study entry: >= 2 years Exclusion Criteria: - Receiving treatment for cardiomyopathy or congestive heart failure - Resting ejection fraction < 50% or fractional shortening < 25% - Uncorrected primary obstructive or severe regurgitative valvular disease, nondilated (restrictive) or hypertrophic cardiomyopathy, or significant systemic ventricular outflow obstruction - Low resting systolic blood pressure: < 90 mm hemoglobin (Hg) - Bradycardia: heart rate < 50 beats per minute (BPM) - Sustained or symptomatic ventricular dysrhythmias uncontrolled with drug therapy or implantable device; significant conduction defects (i.e.: second or third degree atrio-ventricular block or sick sinus syndrome) - History or current clinical evidence of moderate -to-severe obstructive pulmonary disease or reactive airway diseases (i.e.: asthma) requiring therapy - Significant hepatic (serum aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] > 3 time upper limit of normal institutional normal), gastrointestinal, or biliary disorders that could impair absorption, metabolism, or excretion of orally administered medications - Endocrine disorders such as primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism not controlled with medication, or insulin dependent diabetes mellitus - Females of child bearing potential who are pregnant, lactating, or sexually active and not taking adequate contraceptive precautions (i.e.: intrauterine device [IUD] or oral contraceptives for 3 months prior to entry into the study) - History of drug sensitivity or allergic reaction to alpha- or beta-blockers - Anemia (hematocrit < 28%) - Use of an investigational drug or beta adrenergic blockers, including metoprolol, sotalol, within 30 days of randomization - Use of select cytochrome P450 2D6 (CYP2D6) inhibitor medications - Inability to swallow pills - Unwillingness or inability to cooperate, or, for the parents or guardians of minors, to give consent, or for the child to give assent, or any condition of sufficient severity to impair cooperation with the study - Use of any other blood pressure lowering medication for treatment of hypertension, within 30 days of randomization |
Country | Name | City | State |
---|---|---|---|
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
United States | University of Michigan, C.S. Mott Children's Hospital | Ann Arbor | Michigan |
United States | City of Hope Medical Center | Duarte | California |
United States | St. Jude Childrens Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
City of Hope Medical Center | National Cancer Institute (NCI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | LV thickness-dimension ratio (LV T-D), reported in terms of LV posterior wall dimension in systole and LV dimension based on the internal diameter in diastole | Z-scores appropriately transformed to normality as necessary. The analysis will be conducted using the linear mixed-effects model approach for normally distributed data, to account for correlation among repeated measurements within individuals. This may be done using the generalized estimating equation (GEE) approach without the random effects or by the restricted maximum likelihood estimation (REML) approach with random effects. Various covariance structures will be assumed, including the unstructured, compound symmetry, and autoregressive lag-1 correlation. Implemented using GENMOD & MIXED. | Up to 24 months | |
Secondary | Echocardiographic efficacy measures, including afterload and systolic and diastolic measurements | Evaluated in the manner described for primary outcome based on testing the significance of the interaction of time by group indicator variables. The distribution of continuous variables will be examined graphically and appropriate transformations made before applying analytical methods based on normal assumption. | Up to 24 months | |
Secondary | Blood biomarkers of myocardial remodeling and CHF risk, including cardiac troponins (cTn), blood natriuretic peptide (BNP), and galectin-3 | Treated as continuous measures. The linear mixed effects model for between group comparisons of measures from the 5 time points will be applied. The unstructured mean model and linear in time model will be employed. | Up to 24 months | |
Secondary | Grade 2-4 toxicities, assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 | The number of grade 2-4 toxicities observed will be tabulated by treatment arm. Differences by treatment arm will be evaluated using Fisher exact tests. | Up to 24 months | |
Secondary | Frequency of individuals with elevated liver function measurements (bilirubin, AST, ALT) | Compared between treatment groups using an exact test on 2 x 2 tables, stratified on CYP2D6. Logistic regression analysis will also be used to compare the trends in liver function levels between the treatment groups. Procs MIXED and GLIMMIX will be used for longitudinal analysis of normally and non-normally distributed data, respectively. Proc GENMOD will also be used for normally and non-normally distributed data. | Up to 24 months | |
Secondary | Subjective safety and tolerability measures, including treatment adherence as measured by pill counts and patient reported symptoms | Voluntary withdrawals will be examined at the end of the study by comparing the percent of withdrawals between the treatment groups using a chi-square test or Fisher's exact test. Patient reported symptoms will be scored as a 5-point Likert-type scale in response to questions on how much patients are bothered by certain symptoms. The responses will be treated as normally distributed, as ordinal or dichotomized variable, and the linear mixed effects model or generalized linear mixed effects model will be applied to compare changes between treatment groups. | Up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02235051 -
Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
|
N/A | |
Completed |
NCT01439945 -
Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Completed |
NCT01641068 -
Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms
|
N/A | |
Not yet recruiting |
NCT05403671 -
Fit for Everyday Life - Increasing Exercise and Physical Activity in Those Rehablilitating From Cancer
|
N/A | |
Completed |
NCT00246818 -
Effect of Tai Chi Vs. Structured Exercise on Physical Fitness and Stress in Cancer Survivors
|
Phase 2 | |
Completed |
NCT02559557 -
Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects
|
N/A | |
Completed |
NCT00956475 -
Quality of Life in Younger Leukemia and Lymphoma Survivors
|
Phase 1 | |
Completed |
NCT02032121 -
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors
|
N/A | |
Completed |
NCT00932997 -
Survivorship Booklets With or Without Individual Telephone Sessions in Increasing Knowledge About the Impact of Breast Cancer in African American and Latina Breast Cancer Survivors
|
N/A | |
Completed |
NCT02566408 -
Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity
|
N/A | |
Completed |
NCT02985411 -
Harvest for Health in Older Cancer Survivors
|
N/A | |
Completed |
NCT00915889 -
Psychosocial Support for African-American, Latina-American, or European-American Cervical Cancer Survivors
|
N/A | |
Completed |
NCT02518308 -
Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer
|
N/A | |
Completed |
NCT03307044 -
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
|
N/A | |
Terminated |
NCT03781778 -
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
|
Phase 2 | |
Completed |
NCT03520283 -
Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors
|
N/A | |
Completed |
NCT02662335 -
Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors
|
N/A | |
Completed |
NCT00713505 -
Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction
|
N/A | |
Recruiting |
NCT03913962 -
Health and Exercise Response in Children With Chronic and Auto-immune Pathologies
|
N/A |